Ahlin Fredrik, Arfvidsson John, Vargas Kris G, Stojkovic Stefan, Huber Kurt, Wojta Johann
3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen hospital, Vienna, Austria; Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen hospital, Vienna, Austria.
Vascul Pharmacol. 2016 Jun;81:15-21. doi: 10.1016/j.vph.2016.04.001. Epub 2016 Apr 13.
Coronary artery disease (CAD) and its complications remain the most common cause of death worldwide. Cardiac troponins (cTn) are standard biomarkers used today for diagnosis and risk stratification of myocardial infarction (MI). Increasing efforts are made to develop additional, new biomarkers for more effective and safe rule-in and rule-out of MI patients at the emergency department. During the past decade, microRNAs (miRNAs) have emerged as new, potential diagnostic biomarkers in several diseases, including MI. In this review, we aimed to summarize some of the prominent studies in the field, and discuss the potential value of miRNAs in the diagnosis of MI.
冠状动脉疾病(CAD)及其并发症仍然是全球最常见的死亡原因。心肌肌钙蛋白(cTn)是目前用于心肌梗死(MI)诊断和风险分层的标准生物标志物。人们正在加大努力开发更多新的生物标志物,以便在急诊科更有效、安全地对MI患者进行确诊和排除。在过去十年中,微小RNA(miRNA)已成为包括MI在内的多种疾病中新的潜在诊断生物标志物。在本综述中,我们旨在总结该领域的一些重要研究,并讨论miRNA在MI诊断中的潜在价值。